Daré Bioscience wins new US patent covering topical lopinavir-ritonavir formulation for DARE-HPV program
Bitget2026/09/28 12:20- Daré Bioscience secured U.S. Patent No. 12,678,439 covering topical lopinavir-ritonavir formulations for HPV-related cervical disorders.
- Protection is expected to extend into at least 2039, strengthening IP around its investigational DARE-HPV vaginal insert program.
- DARE-HPV is in a Phase 2 trial in about 100 women; topline results are expected in 2027.
- Program funding includes about USD 10 million from ARPA-H, alongside a USD 2 million NIAID award.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
